Drug results: 2
| foscarbidopa | Foscarbidopa and foslevodopa combination (ABBV-951) was aproved by PMDA for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. Foscarbidopa and foslevodopa are prodrugs of carbidopa and levodopa, respectively. They have higher solubility than their parent compounds, which allows them to be administered as a continuous subcutaneous infusion. |
|
| foslevodopa | Foslevodopa and foscarbidopa combination (ABBV-951) was aproved by PMDA for the treatment of motor fluctuations in patients with advanced Parkinson’s disease. Foscarbidopa and foslevodopa are prodrugs of carbidopa and levodopa, respectively. They have higher solubility than their parent compounds, which allows them to be administered as a continuous subcutaneous infusion. |
|








Citing DrugCentral © 2026.
License